Adult WT or SUR2KO female mice at the age of 9 wks were subject to ovariectomization [25 (link)]. These mice were subsequently implanted with 17β-estradiol (E2) or placebo pellets (0.1 μg/g/day, 21-day release, Innovative Research of America, Sarasota, FL). All mice received our I-R protocol on Day 18-20.
17β estradiol e2
Manufactured by Innovative Research
Sourced in United States
17β-estradiol (E2) is a steroid hormone that serves as the primary female sex hormone. It plays a crucial role in the regulation of the menstrual cycle and the development and maintenance of female reproductive organs and secondary sexual characteristics.
Automatically generated - may contain errors
Lab products found in correlation
Placebo pellet, by Innovative Research (2 mentions)
Matrigel, by BD (1 mentions)
Cl316 243, by Bio-Techne (1 mentions)
Fty720 fingolimod, by Cayman Chemical (1 mentions)
Okadaic acid, by Abcam (1 mentions)
60 day release pellets, by Innovative Research (1 mentions)
Pepstatin, by Merck Group (1 mentions)
Fast sybr green pcr master mix, by Thermo Fisher Scientific (1 mentions)
Rnase inhibitor, by Thermo Fisher Scientific (1 mentions)
Oligo d t 16, by Thermo Fisher Scientific (1 mentions)
Real time pcr primers, by Merck Group (1 mentions)
Mulv reverse transcriptase, by Thermo Fisher Scientific (1 mentions)
Rotenone, by Merck Group (1 mentions)
Glycerol, by Merck Group (1 mentions)
Glucose 6 phosphate (g6p), by Merck Group (1 mentions)
Glucose 6 phosphate dehydrogenase, by Merck Group (1 mentions)
Leupeptin, by Merck Group (1 mentions)
Rneasy mini kit, by Qiagen (1 mentions)
Recombinant mouse il 25, by R&D Systems (1 mentions)
Siglecf e50 2440, by BD (1 mentions)
8 protocols using 17β estradiol e2
1
Ovariectomized Mice Estradiol Implant
2
Humanized Mammary Tumor Xenograft Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The care of animals and all animal procedures were conducted in accordance with a protocol approved by the Tufts University Institutional Animal Care and Use Committee, and the approval number for animal research is A-3775-01. Colonies of NOD/SCID mice were maintained in house. Mice were given food and water ad libitum. To humanize mice, mammary epithelium was removed from the fourth mammary glands of 3 week-old NOD/SCID females, and RMF-EG cells were injected into the fat pad as described [31] (link). Two weeks post-humanization, GFP virus-infected cells (100,000 per gland) were co-mixed with primary breast stromal cells (2.5×105 per gland) in a 1∶1 mixture of collagen and Matrigel (BD Biosciences) and injected into humanized fat pads. Mice were ovariectomized at the time of transplantation and implanted with 0.1 mg 17β-estradiol (E2), 10 mg progesterone (P4), 0.1 mg E2/10 mg P4 or placebo pellets (Innovative Research of America) to model serum levels of hormones present during the luteal phase of the menstrual cycle. Tissue was collected 8 weeks following surgery and imaged for GFP expression.
3
Intracerebroventricular Injection and Ovariectomy Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Intracerebroventricular injection was performed as previously described (22 (link)). Briefly, mice were anesthetized with isoflurane, a small incision was made in the scalp, and an injection was achieved at a point 1 mm lateral and 1 mm caudal to bregma, at a depth of 2 mm. The volume for all intracerebroventricular injections was 1 μL in a 10-μL syringe (Hamilton). The syringe was left in place for 1 min to allow for infusate diffusion. The proper injection site was verified in pilot experiments by administration and localization of Evans Blue dye. Intracerebroventricular administration of okadaic acid (OA, 20 ng; Abcam) and FTY720 (fingolimod, 2.5 µg; Cayman) was performed twice a week (23 (link),24 (link)).
Ovariectomies were performed in 10-week-old mice, as described previously (25 (link)). For peripheral estrogen treatment, pellets releasing vehicle or 17β-estradiol (E2) (0.25 mg, 60-day release pellets; Innovative Research of America) were implanted 1 week after ovariectomy. The β3-adrenergic receptor agonist CL316243 (0.5 mg/kg; Tocris) was administered daily via i.p. route (26 (link)).
Ovariectomies were performed in 10-week-old mice, as described previously (25 (link)). For peripheral estrogen treatment, pellets releasing vehicle or 17β-estradiol (E2) (0.25 mg, 60-day release pellets; Innovative Research of America) were implanted 1 week after ovariectomy. The β3-adrenergic receptor agonist CL316243 (0.5 mg/kg; Tocris) was administered daily via i.p. route (26 (link)).
4
Quantification of Estradiol Signaling
5
Comprehensive Immunophenotyping of Mouse Cells
6
Ovariectomy and Estradiol Replacement in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
At 7 to 10 weeks of age, female mice were ovariectomized or sham-operated, under isoflurane (Baxter Medical Ab, Kista, Sweden) anesthetization by inhalation. Carprofen (Orion Pharma AB, Animal Health, Sollentuna, Sweden) was administered subcutaneously as postoperative analgesic.
Mice were implanted with slow release pellets containing placebo or 17β-Estradiol (E2) at the time of ovx (0.05 mg E2/kg/day; 90-day release, Innovative Research of America, Sarasota, FL). The animals were randomly divided into 3 groups per genotype (6–9 mice per group): sham + placebo, ovx + placebo or ovx + E2. Treatment continued until study termination (4 weeks).
Mice were implanted with slow release pellets containing placebo or 17β-Estradiol (E2) at the time of ovx (0.05 mg E2/kg/day; 90-day release, Innovative Research of America, Sarasota, FL). The animals were randomly divided into 3 groups per genotype (6–9 mice per group): sham + placebo, ovx + placebo or ovx + E2. Treatment continued until study termination (4 weeks).
7
Estradiol Administration in CIA Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were administered subcutaneous slow-release implants with 17β-estradiol (E2; Innovative Research of America, Sarasota, FL, USA) or placebo at the time point of OVX, resulting in daily doses of 0.83 μg of E2 per mouse. In one CIA experiment, mice received only 3 days of E2 treatment, administered by subcutaneous injections during days 20 to 22, using 17β-estradiol-3-benzoate (1 μg/mouse/day: Sigma-Aldrich) in inert oil (Miglyol 812; Recip, Årsta, Sweden), and control mice received oil only. As described earlier, mice treated with estradiol in doses similar to those used herein obtain serum estradiol of 10 to 25 pg/ml, which in healthy mice corresponds to low diestrus levels [26 (link)]. Successful OVX and estrogen treatment was confirmed by weighing uteri at termination (data not shown).
8
Hormone Pellet Implantation in Animals
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!